FASL Antikörper

Produktnummer ABIN1105941

Dieses Anti-FASL-Antikörper ist ein Hamster Monoklonal-Antikörper zur Detektion von FASL in EIA. Geeignet für Human.

Kurzübersicht für FASL Antikörper (ABIN1105941)

Target: FASL (Fas Ligand (TNF Superfamily, Member 6) (FASL))

Reaktivität: Human

Wirt: Hamster

Klonalität: Monoklonal

Konjugat: Dieser FASL Antikörper ist unkonjugiert

Applikation: Enzyme Immunoassay (EIA)

Klon: 4H9

Produktdetails anti-FASL Antikörper

Spezifität: This antibody reacts with Fas Ligand.

Kreuzreaktivität (Details): Species reactivity (tested):Human

Aufreinigung: Protein A agarose

Immunogen: Recombinant human Fas Ligand

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1.0 mg/mL

Buffer: PBS containing 50 % glycerol, pH 7.2. Contains no preservatives.

Konservierungsmittel: Without preservative

Handhabung: Avoid repeated freezing and thawing.

Lagerung: -20 °C

Informationen zur Lagerung: Store (in aliquots) at -20 °C.

Details zu FASL

Target: FASL (Fas Ligand (TNF Superfamily, Member 6) (FASL))

Andere Bezeichnung: CD178 / Fas Ligand

Hintergrund: Fas ligand (FasL/CD178/CD95L) is a type II-membrane protein, belonging the tumor necrosis factor (TNF)/nerve growth factor (NGF) family. It is known that engagement of Fas (receptor of FasL) by FasL causes apoptotic cell death. FasL is predominantly expressed in activated T lymphocytes and Natural Killer (NK) cells and expressed in the tissues of the immune-privilege sites such as the testis and eye. On the other hand, Fas is expressed in various tissues with abundant expression in the thymus, liver, heart, and kidney. Furthermore, a variety of cancers such as melanomas were found to express FasL in addition to Fas. It is said that the Fas/FasL system is involved in the deletion of dangerous activated or autoreactive T and B cells, and in turn plays a role in human diseases such as fulminant hepatitis, AIDS, cancers and other diseases involving CTL-induced tissue destruction. Furthermore, FasL can be used as an immune-suppressive agent. Rejection of transplants is mediated by activated T cells that may express functional Fas. If a transplanted tissue is engineered to express FasL or is co-transplanted with FasL-expressing cells, the transplant may be tolerated.Synonyms: APT1LG1, APTL, Apoptosis antigen ligand, CD95L protein, FASL, FASLG, Fas antigen ligand, TNFSF6, Tumor necrosis factor ligand superfamily member 6

Gen-ID: 356

NCBI Accession: NP_000630

UniProt: P48023

Pathways: Apoptose, EGFR Signaling Pathway, Production of Molecular Mediator of Immune Response, Positive Regulation of Endopeptidase Activity